A novel peptide specifically binding to VEGF receptor suppresses angiogenesis in vitro and in vivo

作者：Zhang, Yuan; He, Bifang; Liu, Kun; Ning, Lin; Luo, Delun; Xu, Kai; Zhu, Wenli; Wu, Zhigang; Huang, Jian^*; Xu, Xun^*

来源：Signal Transduction and Targeted Therapy, 2017, 2(1): e17010.

DOI：10.1038/sigtrans.2017.10

• MACULAR DEGENERATION
• PHAGE DISPLAY
• TRAP-EYE
• CORNEAL NEOVASCULARIZATION
• PHASE-2
• OBESITY
• TARGET
• MIMODB
• FUTURE
• MOUSE

Vascular endothelial growth factor (VEGF), one of the most important angiogenic factors, plays an essential role in both physiological and pathological angiogenesis through binding to VEGF receptors (VEGFRs). Here we report a novel peptide designated HRHTKQRHTALH (peptide HRH), which was isolated from the Ph.D. -12 phage display library using VEGFR-Fc fusion protein as the bait. This peptide was found to dose-dependently inhibit the proliferation of human umbilical vein endothelial cells stimulated by VEGF. The anti-angiogenesis effect of the HRH peptide was further confirmed in vivo using the chick chorioallantoic membrane assay, which was also dose-dependent. Besides, peptide HRH was proved to inhibit corneal neovascularization in an alkali-burnt rat corneal model and a suture-induced rat corneal model. Taken together, these findings suggest that the HRH peptide can inhibit angiogenesis both in vitro and in vivo. Consequently, the HRHTKQRHTALH peptide might be a promising lead peptide for the development of potential angiogenic inhibitors.

• 出版日期2017
• 单位上海交通大学; 电子科技大学